We are live on ! Find out more
THNR icon

Amplify Weight Loss Drug & Treatment ETF
THNR

2 hedge funds and large institutions have $187K invested in Amplify Weight Loss Drug & Treatment ETF in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

29.52% less ownership

Funds ownership: 35.86% → 6.34% (-30%)

50% less funds holding

Funds holding: 4 → 2 (-2)

97% less capital inflows, than outflows

Capital inflows: $42.4K | Capital outflows: $1.25M

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$42.4K

Top Sellers

Rank Fund Capital Flow
1
GTS Securities
GTS Securities
Florida
-$719K
2
Jane Street
Jane Street
New York
-$536K

THNR Hedge Fund Activity: Q2 2025 in Review

2 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q2 2025, worth a combined $187K — down 87% from $1.39M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of THNR and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $42.4K. The largest seller was GTS Securities, exiting entirely with an estimated $719K sold.

  • 2 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q2 2025, down from 4 in Q1 2025.
  • Funds reported $187K of Amplify Weight Loss Drug & Treatment ETF stock for Q2 2025, down 87% quarter-over-quarter.
  • 0 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q2 2025 and 2 closed out, a net change of -2 holders.
  • The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q2 2025 was UBS Group, an estimated $42.4K added.
  • The largest Amplify Weight Loss Drug & Treatment ETF seller in Q2 2025 was GTS Securities, an estimated $719K sold.

Based on aggregated 13F filings for Q2 2025.